Medicines discovery in the 21st century: the case for a stakeholder corporation

Dixon, John; England, Paul; Lawton, Geoff; Machin, Peter; Palmer, Alan M.

doi:10.1016/j.drudis.2010.07.004

Cited by 6 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmaceutical industry is undergoing a period of great change, reacting to the 'patent cliff', with fewer blockbusters being launched, R&D productivity at record low levels and the requirement for more niche products to serve new markets (Dixon et al 2010). Many organisations are now actively reviewing their global footprints and legacy supply chains, driven by, for example, growth in emerging markets, and questioning whether they have the optimal architecture for manufacturing in the future .…”

Section: Introductionmentioning

confidence: 99%

Reconfiguring global pharmaceutical value networks through targeted technology interventions

Harrington

Phillips

Srai

2016

International Journal of Production Research

View full text Add to dashboard Cite

Targeting a series of advanced manufacturing technology (AMT) 'interventions' provides the potential for significant step changes across the pharmaceutical value chain, from early stage 'system discovery' and clinical trials, through to novel service supply models. This research explores future value network configurations which, when aligned with disruptive shifts in technology (process and digital), may enable alternative routes to medicines production and the delivery of additional value to 'end-users', i.e. patients and health care providers. We draw on a categorisation of AMTs that may enable a shift from the traditional 'batch' and centralised manufacturing paradigm of 'make-to-stock', towards more re-distributed 'continuous' manufacturing and 'make-to-order' models. Despite reported benefits in the academic literature (e.g. reduced footprints, improved quality, enhanced flexibility and inventory savings), current adoption rates of continuous technologies in this sector remain low (c. 5%). This paper presents new data sources, in our study of AMT adoption in a global pharmaceutical context -assessing the barriers to implementation, and the pathways to delivering future continuous manufacturing scenarios. Our findings capture the high level of disparity in viewpoints, highlighting the uncertainties and transformational challenges ahead -in terms of opportunity areas, technological readiness and a future vision for the sector, as a whole.

show abstract

Section: Introductionmentioning

confidence: 99%